SC
BMRN icon

Steph & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Steph & Co’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,488
Closed -$130K – 234
2020
Q4 		$130K Buy
1,488
+45
+3% +$3.57K 0.1% 125
2020
Q3 		$110K Buy
1,443
+124
+9% +$12.5K 0.1% 116
2020
Q2 		$163K Sell
1,319
-532
-29% -$52.9K 0.16% 68
2020
Q1 		$156K Buy
1,851
+194
+12% +$16.7K 0.18% 66
2019
Q4 		$140K Buy
+1,657
New +$125K 0.12% 104

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Steph & Co's BMRN Position: Q1 2021 in Review

Steph & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 1,488 shares — an estimated $130K sold.

Steph & Co first reported a position in BMRN in Q4 2019 and held it in 5 quarters. The position peaked at $163K in Q2 2020. 530 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

  • Steph & Co reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Steph & Co sold 1,488 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $130K.
  • Steph & Co first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 5 quarters.
  • Steph & Co's BioMarin Pharmaceuticals position peaked at $163K in Q2 2020.
  • 530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Steph & Co's 13F filing for Q1 2021, filed 16 Apr 2021.